Oral Answers to Questions

Debate between Mary Glindon and Lord Lansley

Thursday 10th July 2014 Commons Chamber

[Mrs Mary Glindon (North Tyneside) (Lab)]

1. What recent guidance he has given to his ministerial colleagues on making statements to the House before they are made to the media.

[The Leader of the House of Commons (Mr Andrew Lansley)]

The ministerial code is clear: when Parliament is in session, the most important announcements of Government policy should be made to Parliament in the first instance, and I regularly remind my colleagues of that.

[Mrs Glindon]

Does the Leader of the House think that it is acceptable that the media are reporting that the Government have paused the proposed sale of the Land Registry when the Business Secretary has not yet made a statement to the House?

[Mr Lansley]

I am not aware of the media reports to which the hon. Lady refers. I will, of course, look at them, but as far as I am concerned announcements are made to the House first. I cannot always preclude speculation in the press, which is sometimes well informed and sometimes very badly informed. I do not necessarily reach the same conclusion, but I will ensure that I let her know what the situation is.

Business of the House

Debate between Mary Glindon and Lord Lansley

Thursday 20th March 2014 Commons Chamber

[Mr Lansley]

The hon. Gentleman raises an important point. I recognise that his EDM has secured support from a number of Members on both sides of the House, and rightly so, because it is a concern for our constituents that they are not subject to these exploitative and damaging rogue traders and others. I cannot promise a debate immediately, but I will of course raise the matter with my hon. Friends to see whether they can reply to him and other Members or inform the House a little more about how they are addressing some of these issues.

[Mrs Mary Glindon (North Tyneside) (Lab)]

Last week the Government announced that they plan to introduce an early access to medicines scheme. Such a scheme was a central point in the recent report by the all-party group on muscular dystrophy. Will the Leader of the House provide some time to debate the scheme, and will he ask the relevant Minister to meet me, patients and representatives from the Muscular Dystrophy Campaign to discuss it further?

[Mr Lansley]

I will of course ask my hon. Friends at the Department of Health whether they might be able to meet the hon. Lady. I cannot promise an immediate debate, but this is an important issue, and I hope that we may have such an opportunity before too long. The early access to medicines scheme, like the breakthrough fund in America, raises the real possibility that, in addition to what we have already done through the cancer drugs fund, which provides the ability to access licensed medicines, drugs that have evident efficacy and safety can be made available through the NHS, even before the point at which they have been through all the formal licensing processes, for patients who often have relatively few other opportunities.

Business of the House

Debate between Mary Glindon and Lord Lansley

Thursday 16th January 2014 Commons Chamber

[Mr Lansley]

I am grateful to my hon. Friend for that. The Financial Services (Banking Reform) Act 2013 will allow us to make important steps in ensuring that we have a banking system that is not prey to the regulatory failures of the past. None the less, he makes an important point about mis-selling in relation to interest rate swaps. I know that my hon. Friends at the Department for Business, Innovation and Skills are anxious to make progress in settling that. I hope that the new Financial Conduct Authority will see that as one of its priorities.

[Mrs Mary Glindon (North Tyneside) (Lab)]

Following the reply given to my hon. Friend the Member for North West Durham (Pat Glass), will the Leader of the House clarify in what way the significant over-reporting of bovine TB and its associated costs and consequences will be brought before the House?

[Mr Lansley]

The hon. Lady will have heard me say that although there were statistical errors, they will not have affected the surveillance and they will not have directly affected livestock businesses through costs and impacts. When the statisticians have identified and quantified the errors, there will be an opportunity for Ministers to provide information to the House about the nature of the error.

Oral Answers to Questions

Debate between Mary Glindon and Lord Lansley

Tuesday 17th July 2012 Commons Chamber

[Mr Lansley]

It is staggering, isn’t it? In 2010-11, the NHS budget was set by the right hon. Gentleman, not by us. The final accounts for 2011-12 will not be published until the autumn. I wish he would just get up at the Dispatch Box and admit that over the course of this Parliament the coalition Government will increase the NHS budget in England by 1.8% in real terms, which is £12.5 billion in cash, whereas the Wales Audit Office has said that a Labour Government in Wales will cut the NHS budget over the same period by 10% in real terms.

[Mrs Mary Glindon (North Tyneside) (Lab)]

2. What steps he is taking to bring forward legislative proposals on the funding of social care.

Oral Answers to Questions

Debate between Mary Glindon and Lord Lansley

Tuesday 21st February 2012 Commons Chamber

[Mrs Mary Glindon (North Tyneside) (Lab)]

T2. Given that managed clinical networks for neuromuscular conditions can help to reduce the number of unplanned hospital admissions for patients with life-shortening illnesses and save the NHS money, will the Secretary of State commit to establishing such networks with funding from the NHS Commissioning Board?

[Mr Lansley]

As we have set out clearly, we want to promote clinical networks more widely, not just in relation to cancer and stroke, as has been the case in the past. I shall write to the hon. Lady about whether it would be appropriate for neuromuscular conditions and whether it is embraced in any plans that the NHS Commissioning Board and commissioning groups have in place already.

Oral Answers to Questions

Debate between Mary Glindon and Lord Lansley

Tuesday 22nd November 2011 Commons Chamber

[Mrs Mary Glindon (North Tyneside) (Lab)]

T4. Will the Secretary of State agree to meet me, and families living with muscle disease, to discuss the urgent problem of primary care trusts refusing to fund vital cough assist machines, which help to prevent serious and very costly winter respiratory infections for those who are unable to use their lung muscles to cough?

[Mr Lansley]

Of course I, or one of my colleagues, will be glad to meet the hon. Lady to discuss that. I might also say that it was important to have announced, as I did last week, the expansion of ECMO—extracorporeal membrane oxygenation—facilities across England. Those facilities present a life-saving opportunity for people with the severest respiratory disease.

Oral Answers to Questions

Debate between Mary Glindon and Lord Lansley

Tuesday 7th June 2011 Commons Chamber

[Mr Lansley]

As my right hon. Friend the Prime Minister made clear today, we continue to believe that we can achieve more integrated services for patients, and we are determined to do so. That must be at the heart of the way in which reform and modernisation of the NHS deliver improving outcomes for patients. For patients, the results of care, and indeed their experience of it, will be greatly enhanced if it is designed and integrated to meet their needs. We know that that is effective, we know that it works for patients, and we are determined to make it happen. My hon. Friend has given just one example, and an important one, of the way in which hospital and community services can be integrated.

[Mrs Mary Glindon (North Tyneside) (Lab)]

The Prime Minister has stated this afternoon that competition will be an integral part of patient choice. How will the Secretary of State ensure that all patients are able to make a fully informed choice of treatment when market forces fully exist?

[Mr Lansley]

I do not accept the hon. Lady’s premise. We do not intend that there should be an unrestricted market—or a free market, as she described it—in the NHS. It is a regulated, social market with powerful regulations governing how the participants in the provision of care meet their responsibilities. We are very clear that competition is a means to an end. It is not an end in itself; it is there to support the integration and delivery of services in the best interests of patients, but it does include giving patients choice. The hon. Lady highlights an important point. In our consultation earlier this year on the information revolution in the NHS, we set out how we felt we could empower patients, including those for whom in the past the NHS has provided a rather impenetrable route to getting the best treatment. I hope that when we respond to that consultation, we will demonstrate how we will make that better for all patients.

Oral Answers to Questions

Debate between Mary Glindon and Lord Lansley

Tuesday 29th June 2010 Commons Chamber

[Mrs Mary Glindon (North Tyneside) (Lab)]

T6. Every year in the north-east, 300 children are born with congenital heart disease. These very sick children receive expert treatment locally in the world-class cardiothoracic unit at Newcastle’s Freeman hospital. Can the Minister assure my constituents, who value this vital local service, that the findings of Sir Ian Kennedy’s review of children’s heart surgery centres will be implemented without financial constraint?

[Mr Lansley]

I should tell the hon. Lady that it is premature to make any commitment about the review, because we now need to have proper engagement with local people, patients and those who are responsible to focus on how we can make absolutely certain that the outcomes that we achieve for children requiring cardiac surgery are as good as we can possibly make them.